Nitric oxide-releasing aspirin but not conventional aspirin improves healing of experimental colitis

Figure 3 Effect of administration of vehicle, aspirin or indomethacin, non-selective cyclooxygenase inhibitors, a selective cyclooxygenase-1 inhibitor 5-(4-chlorophenyl)-1-​(4-methoxyphenyl)-3-(trifluoromethyl)-​1H-​pyrazole, a selective cyclooxygenase-2 inhibitor (celecoxib) and nitric oxide releasing aspirin, on the area of colonic lesions and alterations in colonic blood flow on day 10 after colitis induction. Mean ± SE of 6-8 rats. ^aP < 0.02 vs vehicle (control); ^cP < 0.05 vs aspirin (ASA)-, indomethacin- and 5-(4-​chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole (SC-560) groups; ^eP < 0.02 vs vehicle, ASA, indomethacin, SC-560 and celecoxib groups. TNBS: Trinitrobenzenesulfonic acid; CBF: Colonic blood flow; NO-ASA: Nitric oxide-ASA.